Rhythm Pharmaceuticals (NASDAQ:RYTM) Upgraded to Moderate Buy at Royal Bank Of Canada

Royal Bank Of Canada upgraded shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) to a moderate buy rating in a research note released on Wednesday,Zacks.com reports.

Several other research firms have also issued reports on RYTM. Morgan Stanley reaffirmed an “overweight” rating and issued a $150.00 price target on shares of Rhythm Pharmaceuticals in a report on Thursday, December 11th. TD Cowen restated a “buy” rating on shares of Rhythm Pharmaceuticals in a research note on Thursday, December 11th. Citigroup reaffirmed an “outperform” rating on shares of Rhythm Pharmaceuticals in a report on Friday, December 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a report on Thursday, January 22nd. Finally, Citizens Jmp raised their price objective on shares of Rhythm Pharmaceuticals from $141.00 to $167.00 and gave the company a “market outperform” rating in a research report on Friday, December 12th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Rhythm Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $131.50.

Rhythm Pharmaceuticals Trading Down 3.2%

Shares of NASDAQ:RYTM traded down $3.35 during mid-day trading on Wednesday, hitting $99.82. 428,738 shares of the company traded hands, compared to its average volume of 637,262. The stock has a 50-day moving average price of $105.69 and a two-hundred day moving average price of $103.23. Rhythm Pharmaceuticals has a 12-month low of $45.90 and a 12-month high of $122.20. The stock has a market cap of $6.66 billion, a P/E ratio of -32.20 and a beta of 2.00.

Insiders Place Their Bets

In related news, insider Pamela J. Cramer sold 3,350 shares of the firm’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $111.00, for a total value of $371,850.00. Following the completion of the sale, the insider owned 20,814 shares of the company’s stock, valued at $2,310,354. This trade represents a 13.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Hunter C. Smith sold 4,385 shares of Rhythm Pharmaceuticals stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $101.26, for a total transaction of $444,025.10. Following the completion of the sale, the chief financial officer owned 110,512 shares in the company, valued at approximately $11,190,445.12. This trade represents a 3.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 25,003 shares of company stock valued at $2,589,015 over the last quarter. 6.10% of the stock is currently owned by company insiders.

Institutional Trading of Rhythm Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its holdings in shares of Rhythm Pharmaceuticals by 39.2% in the 3rd quarter. Vanguard Group Inc. now owns 4,996,427 shares of the company’s stock worth $504,589,000 after purchasing an additional 1,407,313 shares in the last quarter. RA Capital Management L.P. boosted its position in shares of Rhythm Pharmaceuticals by 17.3% during the fourth quarter. RA Capital Management L.P. now owns 6,666,837 shares of the company’s stock valued at $713,618,000 after buying an additional 985,478 shares during the last quarter. Alliancebernstein L.P. increased its holdings in Rhythm Pharmaceuticals by 1,493.8% in the 3rd quarter. Alliancebernstein L.P. now owns 979,682 shares of the company’s stock worth $98,938,000 after buying an additional 918,212 shares in the last quarter. JPMorgan Chase & Co. raised its position in Rhythm Pharmaceuticals by 445.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 783,559 shares of the company’s stock worth $49,513,000 after buying an additional 639,919 shares during the last quarter. Finally, Capital Research Global Investors purchased a new position in Rhythm Pharmaceuticals in the 3rd quarter worth about $60,417,000.

Key Rhythm Pharmaceuticals News

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: RBC Capital initiated coverage with an “outperform” rating, bringing fresh institutional attention and a formal buy-style endorsement that can support demand for the stock. Read More.
• Positive Sentiment: Multiple broker updates and higher price targets (Wells Fargo, Citizens, Morgan Stanley, UBS, TD Cowen) reinforce a bullish analyst consensus and raise forward expectations for Imcivree revenue and valuation upside. Read More.
• Positive Sentiment: A Yahoo Finance feature highlights accelerating Imcivree revenue and updated management targets — an operational narrative that supports medium-term revenue growth if execution continues. Read More.
• Neutral Sentiment: Zacks upgraded RYTM from “strong sell” to “hold” and flagged the company as likely to beat upcoming earnings estimates — these items reduce near-term downside perception but are not definitive catalysts until the earnings release. Read More.
• Negative Sentiment: CFO Hunter C. Smith sold multiple parcels of RYTM shares this week (SEC filings show sales ~3,569–4,385 shares at ~\$101 each). Insider sales often trigger short-term selling pressure and investor concern despite being a small percentage of total holdings. Read More.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.